The company's scientifically validated AI platform, PEDAL, is able to predict with 92% accuracy if a tumor sample will respond to a certain drug compound, allowing for a more informed selection of drug/tumor type combinations for subsequent in-vitro testing. The company is changing its corporate name to Axe Compute Inc. effective December 11, 2025, reflecting a strategic pivot toward broader compute applications.
Cyborg Score Rationale
The company announced progress in its ongoing evaluation of strategic alternatives announced in November 2024, considering a wide range of options including a potential sale of the Company, sale of assets, merger, or licensing agreement. The company implemented a 1-for-15 reverse stock split effective September 30, 2025, primarily intended to help meet Nasdaq's minimum bid price requirement. Limited public revenue data and the strategic alternatives process underscore execution challenges.
Top Insights
In July 2025, the company entered into a $10 million standby equity purchase agreement with Yorkville Advisors to provide flexible funding for drug discovery and repurposing initiatives.
The company is transitioning from ticker POAI to AGPU on or about December 12, 2025, concurrent with corporate name change to Axe Compute Inc.
Core asset is a biobank of more than 150,000 assay-capable human tumor samples with extensive longitudinal drug response data spanning multiple cancer types.
The company has 11-50 employees and was founded in 2002, with specialties in cancer therapeutics, pharmaceutical drug discovery, AI, and oncology research.
Named Competitors
PathAI — AI-powered pathology and drug discovery platform
Exscientia — AI-driven small molecule drug discovery
BenevolentAI — AI platform for drug discovery and development
Recent Developments
(December 2025) Pending name change to Axe Compute Inc. with ticker transition from POAI to AGPU